Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs

Balzarini, 1987, 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis, Mol. Pharmacol., 32, 798 Blakley, 1990, Cytostatic effects of 2′,3′-Dideoxyribonucloesides on trasformed human hemopoietic cell lines, Mol. Pharmacol., 37, 328 Carson, 1988, Bio-chemical genetic analysis of 2′,3′-dideoxyadenosine metabolism in human T lymphocytes, Biochem. Biophys. Res. Commun., 151, 788, 10.1016/S0006-291X(88)80350-4 Cordiali-Fei, 1994, Apoptosis in HIV infection: protective role of IL-2, J. Biol. Regul. Homeost. Agent, 8, 60 Faras, 1973, RNA-directed DNA polymerase of Rous sarcoma virus: initiation of synthesis with 70 S viral RNA as template, J. Mol. Biol., 79, 163, 10.1016/0022-2836(73)90277-5 Fattorossi, 1996, A multiparameter flow cytometric approach to hematopoietic differentiation in vitro, Cytometry, Suppl., 8, 79 Ferlini, 1996, Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques, Cytometry, 24, 106, 10.1002/(SICI)1097-0320(19960601)24:2<106::AID-CYTO2>3.0.CO;2-H Ferlini, 1995, Rhodamine 123: a useful probe for monitoring lymphocyte activation, Cytometry, 21, 284, 10.1002/cyto.990210309 Fischl, 1990, A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome, N. Engl. J. Med., 323, 1009, 10.1056/NEJM199010113231501 Fischl, 1989, Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex, JAMA, 262, 2405, 10.1001/jama.1989.03430170067030 Fischl, 1990, The safety and efficacy of zidovudina (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: double-blind, placebo-controlled trial, Ann. Intern. Med., 112, 727, 10.7326/0003-4819-112-10-727 Furmansky, 1980, Inhibition by 2′,3′-Dideoxythymidine of retroviral infection of mouse and human cells, Cancer Lett., 8, 307, 10.1016/0304-3835(80)90146-9 Heagy, 1991, Inhibition of immune functions by antiviral drugs, J. Clin. Invest., 87, 1916, 10.1172/JCI115217 Hubscher, 1994, DNA replication and chemotherapy, Physiol. Rev., 74, 259, 10.1152/physrev.1994.74.2.259 Kroemer, 1995, The biochemistry of programmed cell death, FASEB J., 9, 1277, 10.1096/fasebj.9.13.7557017 Langtry, 1989, Zidovudine: a review on its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy, Drugs, 37, 408, 10.2165/00003495-198937040-00003 Lisignoli, 1993, In vitro immunotoxicity of +2′-deoxy-3′-thiacytidine, a new anti HIV agent, Clin. Exp. Immunol., 92, 455, 10.1111/j.1365-2249.1993.tb03420.x Lyons, 1994, Determination of lymphocyte division by flow cytometry, J. Immunol. Meth., 171, 131, 10.1016/0022-1759(94)90236-4 Malorni, 1993, N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells, FEBS Lett., 327, 75, 10.1016/0014-5793(93)81043-Y Meng, 1992, Combination therapy with zidovudine and dideoxycytidine in patients with advances human immunodeficiency virus infection: a phase I/II study, Ann. Intern. Med., 116, 13, 10.7326/0003-4819-116-1-13 Merigan, 1991, Treatment of AIDS with combinations of antiretroviral agents, Am. J. Med., 90, 8, 10.1016/0002-9343(91)90405-M Merigan, 1989, Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections, Ann. Inter. Med., 110, 189, 10.7326/0003-4819-110-3-189 Mitsuya, 1986, Inhibition of the in vitro infectivity and cytopathic effect of human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides, 83, 1911 Perno, 1988, Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides, J. Exp. Med., 160, 1111, 10.1084/jem.168.3.1111 Petit, 1996, Mitochondria and programmed cell death: back to the future, FEBS Lett., 396, 7, 10.1016/0014-5793(96)00988-X Richman, 1988, Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection, Am. J. Med., 85, 208 Sailaja, 1996, Azidothymidine induces apoptosis in mouse myeloma cell line Sp2/O, Biochem. Pharmacol., 52, 857, 10.1016/0006-2952(96)82183-6 Simpson, 1989, Studies of the inhibition of mitochondrial DNA replication by 3′-azido-3′-deoxythymidine and other dideoxinucleoside analogs which inhibit HIV-1 replication, Biochem. Pharmacol., 38, 1033, 10.1016/0006-2952(89)90245-1 Skowron, 1990, Alternating and intermittent regimens of zidovudine (3′-azido-3′-deoxythymidine) and dideoxycytidine (2′,3′-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex, Am. J. Med., 88, 20S, 10.1016/0002-9343(90)90417-C Tornevik, 1990, 2′,3′-dideoxycytidine toxicity in cultered human CEM T lymphoblasts: effects of combination with 3′-azido-3′-deoxythymidine and thymidine, Mol. Pharmacol., 38, 237 Ullman, 1986, Genetic analysis of 2′,3′-dideoxycytidine incorporation into cultured human T-lymphoblasts, J. Biol. Chem., 263, 12391, 10.1016/S0021-9258(18)37768-8 Viora, 1995, Down-regulation of interleukin-2 receptor gene activation and protein expression by dideoxynucleosides analogs, Cell. Immunol., 163, 289, 10.1006/cimm.1995.1128 Viora, 1994, Zidovudine effects on murine and human immune responses, Immunol. Infec. Dis., 4, 47 Viora, 1994, Modulatory effects of ddC and ATZ/ddC combination on murine and human immune responses, Cell. Pharmacol., 1, 263 Yarchoan, 1993, Challenges in the therapy of HIV infection, Immunol. Today, 14, 303, 10.1016/0167-5699(93)90050-U